TD Cowen analyst Joseph Thome reiterated a Buy rating on Entrada Therapeutics (NASDAQ: TRDA).The analyst commented, "TRDA reported Q2 net ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE